Revolution Medicines is trading 4.17% higher at $208.20, with Goldman Sachs’ September 24, 2026 coverage initiation, Buy rating and $267 price target appearing to be the primary company-specific catalyst.
- The advance follows a 4.78% gain in the previous session.
- Broader markets are modestly higher, but Revolution Medicines’ move is substantially stronger than major indexes.